MedTrace Logo

XmAb5871 Bioavailability Study

NCT02867098 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-12-08

No results posted yet for this study

Summary

An open label comparison of concentration of the study medication administered intravenously (IV) versus subcutaneously (SC) in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

XmAb5871

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • Xencor, Inc.

    lead INDUSTRY

Principal Investigators

  • Esther Yoon, MD · California Clinical Trials Medical Group - PAREXEL, Early Phase Clinical Unit-Los Angeles

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2016-10-21
Completion
2016-10-21

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02867098 on ClinicalTrials.gov